Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma

Article in Press

Willem M.C. van Aalderen, MD, PhD

,

 Jonathan Grigg, MD

,

 Theresa W. Guilbert, MD, MS

,

 Nicolas Roche, MD, PhD

,

Elliot Israel, MD

,

 Richard J. Martin, MD

,

 Gene Colice, MD

,

 Dirkje S. Postma, MD, PhD

,

 Elizabeth V. Hillyer, DVM

,

 Anne Burden, MSc

,

 Victoria Thomas, MSc

,

 Julie von Ziegenweidt

,

 David Price, FRCGP

Publication stage: In Press Corrected Proof

Open Access

DOI: http://dx.doi.org/10.1016/j.jaip.2015.04.012

Open access funded by the Author(s)

Article Info

• Abstract
• Full Text
• Images
• References
• Supplemental Materials

Background

Because randomized controlled trials of established pediatric asthma therapies are expensive and difficult to perform, observational studies may fill gaps in the evidence base.

Objectives

To compare the effectiveness of representative small-particle inhaled corticosteroid (ICS) with that of standard size–particle ICS for children initiating or stepping up ICS therapy for asthma (analysis 1) and to compare the effectiveness of ICS dose step-up using small-particle ICS with adding long-acting β2-agonist (LABA) to the ICS (analysis 2).

Allergic Diseases - New Insights. Open access book

Medicine

Edited by Celso Pereira , ISBN 978-953-51-2044-5, 244 pages, Publisher: InTech, Chapters published April 22, 2015 under CC BY 3.0 license
DOI: 10.5772/58513

Allergic diseases are one of the most prevalent diseases in the present with an undeniable correlation with development conditions and with the surrounding environment. Thus, it becomes imperative that the gradual understanding of the pathophysiology and treatment strategies may be convenient for wide dissemination in the scientific community. The chapters included in the book Allergic diseases New Insights addressed a variety of important topics related to distinct aspects related to allergy. The contribution of outstanding expert authors from many countries provided update reviews on basic, clinical and treatment aspects and put in evidence further research regarding the knowledge of immune system responses and key points of allergic inflammatory reactions.

Effect of Lipopolysaccharide on Glucocorticoid Receptor Function in Control Nasal Mucosa Fibroblasts and in Fibroblasts from Patients with Chronic Rhinosinusitis with Nasal Polyps and Asthma

• PLoS One
• v.10(5); 2015
• PMC4420770

PLoS One. 2015; 10(5): e0125443.

Published online 2015 May 5. doi:  10.1371/journal.pone.0125443

PMCID: PMC4420770

Laura Fernández-Bertolín,1,2 Joaquim Mullol,1,2,3 Mireya Fuentes-Prado,1,2 Jordi Roca-Ferrer,1,2 Isam Alobid,1,2,3César Picado,1,2,4 and Laura Pujols1,2,*

Christine Beeton, Academic Editor

Author information ► Article notes ► Copyright and License information ►

Abstract

Background

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease of the upper airways frequently associated with asthma. Bacterial infection is a feature of CRSwNP that can aggravate the disease and the response to glucocorticoid treatment.

Objective

We examined whether the bacterial product lipopolysaccharide (LPS) reduces glucocorticoid receptor (GR) function in control nasal mucosa (NM) fibroblasts and in nasal polyp (NP) fibroblasts from patients with CRSwNP and asthma.

Increase in the Level of Proinflammatory Cytokine HMGB1 in Nasal Fluids of Patients With Rhinitis and its Sequestration by Glycyrrhizin Induces Eosinophil Cell Death

 Table of Contents > Abstract Original Article  Open Access        Clin Exp Otorhinolaryngol. 2015 Jun;8(2):123-128. English. Leonardo Cavone,1 Caterina Cuppari,2 Sara Manti,2 Luisa Grasso,2 Teresa Arrigo,2 Luca Calamai,1 Carmelo Salpietro,2 and Alberto Chiarugi1 Go to: Abstract Objectives The nuclear protein high mobility group protein box 1 (HMGB1) is a proinflammatory mediator that belongs to the alarmin family of proinflammatory mediators, and it has recently emerged as a key player in different acute and chronic immune disorders. Several lines of evidence demonstrate that HMGB1 is actively released extracellularly from immune cells or passively released from necrotic cells. Because of the ability of HMGB1 to sustain chronic inflammation, we investigated whether the protein is present in nasal fluids of patients with different forms of rhinitis.

Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)-11: cross-linking terms and unmet needs

Research

Luciana Kase Tanno¹, Moises Calderon², Nikolaos G. Papadopoulos³⁴, Pascal Demoly^5* and on behalf of the EAACI/WAO Task force of a Global Classification of Hypersensitivity/Allergic diseases

Clinical and Translational Allergy 2015, 5:20  doi:10.1186/s13601-015-0063-x

Abstract (provisional)

Background With the aim of actively contributing to the ongoing 11th International Classification of Diseases (ICD) revision, an international collaboration led by the European Academy of Allergy and Clinical Immunology (EAACI) has decided to revise the classification of hypersensitivity/allergic diseases and to validate it for ICD-11 by crowdsourcing the allergist community. However, understanding that the construction of a classification was necessary but not sufficient, we developed a mapping strategy in the attempt to better fit it to the ICD-11 linearization structure.

Serum tryptase detected during acute coronary syndrome is significantly related to the development of major adverse cardiovascular events after 2 years

Research

Elide Anna Pastorello^1*, Laura Farioli², Laura Michelina Losappio¹, Nuccia Morici³, Matteo Di Biase⁴, Michele Nichelatti⁵, Jan Walter Schroeder¹, Luca Balossi¹ and Silvio Klugmann³

Clinical and Molecular Allergy 2015, 13:14  doi:10.1186/s12948-015-0013-0

Published: 2 June 2015

Abstract

Background

One of the greatest challenges in cardiovascular medicine is to define the best tools for performing an accurate risk stratification for the recurrence of ischemic events in acute coronary syndrome (ACS) patients.

Whistles and wheezes: don't miss diseases

Arch Dis Child Educ Pract Ed 2015;100:132-143 doi:10.1136/archdischild-2013-304604

1. J Cyriac, 
2. K Huxstep

Abstract

Upper airway obstruction (UAO) in infants and children has a broad spectrum of presentations including benign self-resolving conditions, from mild croup, to critical life-threatening conditions which, though uncommon now, require prompt recognition and effective multidisciplinary collaborative management to achieve a good outcome.

Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria

Acta Derm Venereol. 2015 Jun 3. doi: 10.2340/00015555-2150. [Epub ahead of print]

Abajian M1, Curto-Barredo L, Krause K, Santamaria E, Izquierdo I, Church MK, Maurer M, Giménez-Arnau A.

Author information

Abstract

Chronic cold urticaria (ColdU) is a rare disease characterized by mast cell-mediated wheals and angioedema following cold exposure. Second-generation H1-antihistamines, such as rupatadine, are the recommended first-line therapy. As of yet, the effects of rupatadine up-dosing on development of ColdU symptom have only been partially characterized.